Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06766630

Exploring the Feasibility of Silk Fibroin Surgical Mesh in Rotator Cuff Tears Repair Enhancement

Rotator cuff tears result in shoulder joint pain and movement disorders, affecting patients' daily lives. The incidence rate rises with age and can be as high as 54% among people over 60 years old. Most rotator cuff tears are unable to heal spontaneously, and the tear area may gradually expand over time. Currently, the main surgical treatment for rotator cuff tears is to use suture anchors to stitch the rotator cuff tendon tissue back to the original anatomical insertion point. Large rotator cuff tears are often accompanied by fat infiltration and tendon retraction. When forcefully sutured, the tension is relatively high, which may lead to non-healing and re-tearing of the rotator cuff. Research indicates that the re-tear rate after rotator cuff tear repair is 20% - 30%, and this probability can reach 40% - 50% for large rotator cuff tears. For these irreparable and large tears, rotator cuff repair typically requires patch augmentation techniques. Surgeries are based on restoring the force couple effect of the rotator cuff as much as possible and covering it with repair materials to achieve reinforcement. Silk fibroin surgical mesh is made of silk fibroin which has good biocompatibility and can be generally placed in the area of rotator cuff tears that cannot be repaired through conventional surgeries. By providing support to the injured rotator cuff tissue, it improves the repair effect. It can reestablish the integrity of the rotator cuff, reducing mechanical tension at the repair site and maintaining the stability of the glenohumeral joint. Besides, it can also promote tissue healing, and cell infiltration and growth, thereby facilitating the biological repair of the injured rotator cuff and reducing the occurrence of postoperative re-tears.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Location status: Recruiting

Location contact

Weiliang Shen

CONTACT

[email protected]

86 137 5710 1563

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preoperative:
  • Age range of 50-75 years old (inclusive), gender not limited;
  • Patients who require surgery due to rotator cuff tears detected by clinical and MRI examination;
  • Evaluated as type IV and above according to Sugaya classification criteria;
  • Patients with persistent or recurrent pain in the shoulder for more than 3 months;
  • Full layer tendon tear of 1-5cm or full layer or complete tear of supraspinatus and/or infraspinatus tendon;
  • History of non-surgical treatment failure;
  • Understand the purpose of the trial, cooperate with surgical treatment and follow-up, voluntarily participate in the trial and sign an informed consent form;

Intraoperative:

  • Confirmed as a full-thickness tear of 1-5cm on the rotator cuff;
  • Tendons can cover more than 50% of the humeral greater tuberosity of the shoulder joint.

Exclusion criteria

  • 1. Pregnant and lactating women; 2.Individuals with contraindications for surgery or anesthesia, as well as those who are allergic to known ingredients of implanted products; 3. Unable to undergo MRI examination due to claustrophobia and other reasons; 4. Individuals with a history of rotator cuff repair on the affected side, or combined with other bone, joint, or muscle soft tissue injuries in the same limb; 5.Patients with subscapular muscle injury; 6.Those with any combination of diseases or symptoms that may affect the evaluation of efficacy, such as Hamada classification of grade 3 shoulder joint disease; 7.Those with residual rotator cuff tendon fatty infiltration ≥ grade 3 by Goutallier classification; 8.Individuals who have taken oral steroids or received steroid injections within 6 weeks prior to surgery; 9.Those who have participated in other interventional clinical trials within the past 3 months prior to the conduct of this trial; 10. Researchers believe that clinical trial participants who are not suitable for participation include but are not limited to those with uncontrolled blood sugar levels, heavy drinkers, smokers, and others who affect repair and healing.

Treatment and study plan

Silk fibroin surgical mesh

Device

This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein

Primary outcomes

  1. Re-tear rate at 12 months postoperatively

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Re-tear rate at 6 months postoperatively

    Time frame: From enrollment to 6 months after surgery

  2. Constant-Murley Score postoperatively

    Time frame: From enrollment to the end of treatment at 12 months

  3. Oxford Shoulder Score postoperatively

    Time frame: From enrollment to the end of treatment at 12 months

  4. Degree of muscle atrophy

    Time frame: From enrollment to the end of treatment at 12 months

  5. Fatty infiltration grading

    Time frame: From enrollment to the end of treatment at 12 months

  6. Tendon thickness

    Time frame: From enrollment to the end of treatment at 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Jinchun Ye

CONTACT

[email protected]

86 17857158596

Sponsors and collaborators

Lead sponsor

Weiliang Shen, Ph.D., M.D.

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jan 9, 2025
Registry last updated
Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.